When the US Supreme Court held Thursday that the plaintiffs in Alliance for Hippocratic Medicine v. FDA do not have standing to bring a challenge to the FDA's regulation of mifepristone, the justices stopped short of asserting exclusive FDA authority.
Since the Dobbs v. Jackson Women's Health Organization decision, medication abortion has become central to accessing reproductive health services, with ambiguity remaining on whether the FDA or the Supreme Court should regulate such drugs.
Activists argue that both the FDA and the Supreme Court have engaged in political battles over mifepristone, perpetuating the idea that it is unsafe, despite its proven safety and efficacy prior to FDA approval.
Mifepristone's safety and effectiveness were established through peer-reviewed data, predating its approval by the FDA, with a history of successful use in France.
[
add
]
[
|
|
...
]